Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Livzon Pharmaceutical Group ( (HK:1513) ) has shared an update.
Livzon Pharmaceutical Group has established a Remuneration and Assessment Committee under its Board of Directors, effective October 23, 2025. This committee, primarily composed of independent non-executive directors, is tasked with reviewing and making recommendations on remuneration issues, ensuring compliance with Hong Kong and Shenzhen listing rules. This move is expected to strengthen corporate governance and align executive compensation with shareholder interests, potentially impacting the company’s operational transparency and stakeholder trust.
The most recent analyst rating on (HK:1513) stock is a Buy with a HK$48.00 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.
More about Livzon Pharmaceutical Group
Livzon Pharmaceutical Group Inc. operates in the pharmaceutical industry, focusing on the development, production, and distribution of pharmaceutical products. The company is committed to enhancing healthcare through innovative solutions and has a market presence in Hong Kong and Shenzhen.
Average Trading Volume: 1,513,250
Technical Sentiment Signal: Buy
Current Market Cap: HK$34.39B
For an in-depth examination of 1513 stock, go to TipRanks’ Overview page.